Gregory Weaver

Biography

Mr. Weaver joined the Egalet board of directors effective February 5, 2014, the date of the listing of our common stock on the NASDAQ Global Market. As of October 2017, Mr. Weaver is Chief Financial Officer of Eloxx Pharmaceuticals, based in Waltham MA and Tel Aviv, Israel. Previously, from October 2015 to August 2017 Mr. Weaver served as CFO of Prometic Life Sciences, headquartered in Quebec, publicly traded on the TSX, focused on blood protein therapeutics for treatment of rare diseases. From January 2015 to September 2015 Mr. Weaver served as executive vice president and chief financial officer of Oryzon Genomics, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases, based in Barcelona and listed on the Madrid exchange. From September 2013 to October 2014, Mr. Weaver served as the chief financial officer, senior vice president, treasurer and corporate secretary of Fibrocell Science, Inc., a publicly held cell therapy company. From June 2011 to July 2013, Mr. Weaver served as senior vice president and chief financial officer of Celsion Corporation, a publicly held biotechnology company, and was a director and chairman of the audit committee of Celsion’s Board of Directors from 2005 to 2011

Research Interest

Mr. Weaver joined the Egalet board of directors effective February 5, 2014, the date of the listing of our common stock on the NASDAQ Global Market. As of October 2017, Mr. Weaver is Chief Financial Officer of Eloxx Pharmaceuticals, based in Waltham MA and Tel Aviv, Israel. Previously, from October 2015 to August 2017 Mr. Weaver served as CFO of Prometic Life Sciences, headquartered in Quebec, publicly traded on the TSX, focused on blood protein therapeutics for treatment of rare diseases. From January 2015 to September 2015 Mr. Weaver served as executive vice president and chief financial officer of Oryzon Genomics, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases, based in Barcelona and listed on the Madrid exchange. From September 2013 to October 2014, Mr. Weaver served as the chief financial officer, senior vice president, treasurer and corporate secretary of Fibrocell Science, Inc., a publicly held cell therapy company. From June 2011 to July 2013, Mr. Weaver served as senior vice president and chief financial officer of Celsion Corporation, a publicly held biotechnology company, and was a director and chairman of the audit committee of Celsion’s Board of Directors from 2005 to 2011